WO2009080788A2 - Agents antibactériens - Google Patents
Agents antibactériens Download PDFInfo
- Publication number
- WO2009080788A2 WO2009080788A2 PCT/EP2008/068100 EP2008068100W WO2009080788A2 WO 2009080788 A2 WO2009080788 A2 WO 2009080788A2 EP 2008068100 W EP2008068100 W EP 2008068100W WO 2009080788 A2 WO2009080788 A2 WO 2009080788A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen
- halo
- alkyl
- hydroxy
- compound
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 181
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 239000001257 hydrogen Substances 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 72
- 125000005843 halogen group Chemical group 0.000 claims description 64
- 241000894006 Bacteria Species 0.000 claims description 61
- 239000000651 prodrug Substances 0.000 claims description 60
- 229940002612 prodrug Drugs 0.000 claims description 60
- 239000012453 solvate Substances 0.000 claims description 56
- -1 d-ealkyloxy Chemical group 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 34
- 230000005764 inhibitory process Effects 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 208000035143 Bacterial infection Diseases 0.000 claims description 24
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 125000002346 iodo group Chemical group I* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000002689 soil Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 17
- 108020003338 D-alanine-D-alanine ligase Proteins 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 108010059993 Vancomycin Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 12
- 229960003165 vancomycin Drugs 0.000 description 12
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 8
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 7
- 108010013639 Peptidoglycan Proteins 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 150000008574 D-amino acids Chemical class 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010042566 Superinfection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013011 aqueous formulation Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000436 ligase inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- GOWXLMYPMNXKON-UHFFFAOYSA-N 2-(3-aminophenyl)-1,3-benzoxazole-6-carboxylic acid Chemical compound NC1=CC=CC(C=2OC3=CC(=CC=C3N=2)C(O)=O)=C1 GOWXLMYPMNXKON-UHFFFAOYSA-N 0.000 description 2
- INWADWHRALGSMF-UHFFFAOYSA-N 2-(3-nitrophenyl)-1,3-benzoxazole-6-carboxylic acid Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC=CC([N+]([O-])=O)=C1 INWADWHRALGSMF-UHFFFAOYSA-N 0.000 description 2
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
- WHVJDKRJPAKQIO-UHFFFAOYSA-N 3-(1,3-benzoxazol-2-yl)aniline Chemical compound NC1=CC=CC(C=2OC3=CC=CC=C3N=2)=C1 WHVJDKRJPAKQIO-UHFFFAOYSA-N 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 108010041525 Alanine racemase Proteins 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241001326278 Enterococcus faecalis JH2-2 Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000605894 Porphyromonas Species 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- BCDIWLCKOCHCIH-UHFFFAOYSA-M methylphosphinate Chemical compound CP([O-])=O BCDIWLCKOCHCIH-UHFFFAOYSA-M 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- KUHSEZKIEJYEHN-QRLADXQJSA-N (2r)-2-amino-3-hydroxypropanoic acid;(2r)-2-aminopropanoic acid Chemical compound C[C@@H](N)C(O)=O.OC[C@@H](N)C(O)=O KUHSEZKIEJYEHN-QRLADXQJSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
- IIZMXFIPOJXMDN-UHFFFAOYSA-N 2-(2-amino-2-carboxyethyl)-1-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C(N)CC1CC1(C(O)=O)C1=CC=CC=C1 IIZMXFIPOJXMDN-UHFFFAOYSA-N 0.000 description 1
- COBWXWHTWBRLNG-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]propanamide Chemical compound NC(=O)C(C)C1=CC=C(C(F)(F)F)C=C1 COBWXWHTWBRLNG-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AJRGDQWFWJDYDP-UHFFFAOYSA-N 3-chloro-1,2-oxazole Chemical class ClC=1C=CON=1 AJRGDQWFWJDYDP-UHFFFAOYSA-N 0.000 description 1
- PCLFEHAPITXKJL-UHFFFAOYSA-N 5,8-dihydroxy-2-[2-(4-methoxyphenyl)ethyl]chromen-4-one Chemical compound C1=CC(OC)=CC=C1CCC1=CC(=O)C2=C(O)C=CC(O)=C2O1 PCLFEHAPITXKJL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108030007172 D-alanine-D-serine ligases Proteins 0.000 description 1
- 150000008541 D-alanines Chemical class 0.000 description 1
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001522957 Enterococcus casseliflavus Species 0.000 description 1
- 101000850579 Enterococcus faecalis (strain ATCC 700802 / V583) Vancomycin B-type resistance protein VanB Proteins 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 101000850583 Enterococcus faecium Vancomycin/teicoplanin A-type resistance protein VanA Proteins 0.000 description 1
- 241000194030 Enterococcus gallinarum Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical group OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- XCQQWCCZZSBTAN-QRLADXQJSA-N O[C@@H](C(=O)O)C.N[C@H](C)C(=O)O Chemical compound O[C@@H](C(=O)O)C.N[C@H](C)C(=O)O XCQQWCCZZSBTAN-QRLADXQJSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940123317 Sulfonamide antibiotic Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000193462 [Clostridium] innocuum Species 0.000 description 1
- UOLAVGFQBBGYQP-UHFFFAOYSA-N [O-][N+](c1cccc(-c2nc(cc(cc3)C(O)=O)c3[o]2)c1)=O Chemical compound [O-][N+](c1cccc(-c2nc(cc(cc3)C(O)=O)c3[o]2)c1)=O UOLAVGFQBBGYQP-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000019399 azodicarbonamide Nutrition 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 101150046743 ddlB gene Proteins 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical class O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical class OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Definitions
- the present application concerns antibacterial agents, processes for the preparation of the disclosed agents, compositions comprising said agents, and uses of said agents including inter alia therapeutic uses.
- DD-ligases contribute to the synthesis of peptidoglycan, a major component of the bacterial cell wall that is required for bacterial survival.
- DD-ligases catalyse the synthesis of a dimer of D-amino acids in an early step of peptidoglycan synthesis.
- DD-ligases catalyse the formation of a dimer of D-alanine (i.e., D-alanine-D- alanine ligases).
- some DD-ligases can use D-serine or D-lactate instead of one of said two D-alanines to form D-alanine-D-serine dipeptide or D-alanine-D-lactate depsipeptide, respectively.
- DD-ligases with so-altered specificity can be found in vancomycin- resistant Enterococci (VRE), vancomycin-resistant Staphycoccus aureus, or in some species of lactic bacteria, etc.
- Vancomycin is an antibiotic commonly used as a last resort treatment for infections caused by multiresistant Enterococci or S. aureus. Because vancomycin acts by binding to the D-AIa-D-AIa motif, bacteria containing DD-ligases capable of employing other substrates such as D-serine or D-lactate can display resistance to vancomycin.
- D-cycloserine a competitive inhibitor of DD-ligases and of alanine racemase has been used as an antibiotic in the early 1950's and 1960's, but has been largely abandoned due to toxic effects on the central nervous system.
- the antibiotic activity of D-cycloserine appears to be mainly mediated by inhibition of alanine racemase which converts L-AIa to D-AIa.
- methylphosphinate inhibitors display high affinity for DD-ligases, but their use as antibiotics is hampered because their high polarity prevents them from crossing the bacterial membrane and reaching their target.
- More recently described DD-ligase inhibitors include 2-(2-Amino-2- carboxy-ethyl)-1-phenyl-cyclopropanecarboxylic acid, 3-chloro-2,2-dimethyl-N-
- WO 03/074516 discloses 2-(3-nitrophenyl)-1 ,3-benzoxazole-6- carboxylic acid and 2-(3-aminophenyl)-1 ,3-benzoxazole-6-carboxylic acid as intermediates in a synthesis process, but does not attribute any function to said molecules.
- 3-(1 ,3-benzoxazol- 2-yl)aniline has been described as antihelmintic but not as an antibacterial agent.
- the invention addresses the above discussed needs in the art. More specifically, the invention teaches further compounds useful as inhibitors of DD-ligases and as antibacterial agents.
- the present substances may also entail one or more advantages over previously known DD- ligase inhibitors and/or over existing antibiotics.
- the compounds can show improved penetration of bacterial cell membrane, for example as compared to methylphosphinate inhibitors, whereby they can more powerfully act on intact, living bacteria.
- the present molecules are structurally distinct from D-cycloserine and can therefore avoid undesired side effects such as CNS toxicity.
- the molecules have been designed to act selectively on DD-ligases - since D-amino acids are not naturally encountered in eukaryotic cells, this ensures high degree of specificity of the present compounds to bacteria, thereby further reducing the possibility of unwanted side effects.
- DD-ligases represent a so far largely unexploited target, it is expected that bacterial resistance to the present compounds in clinics would be minimal. Also, given that the chemical structure and mode of action of the present molecules is considerably different from other antibiotic classes in common use, said molecules would not display cross- resistance with other existing antibiotics, and therefore could target bacteria that have acquired resistance to such existing antibiotics. For example, because the present molecules target DD-ligase and not the D-AIa-D-AIa dimer, they can be effective against both vancomycin-sensitive and vancomycin-resistant bacteria. Also, since DD-ligases are essential enzymes for all bacteria relying on the existence of a cell wall - which encompass most known pathogenic bacteria - the present compounds are expected to show broad spectrum of activity.
- the invention provides the use of a compound of any of formulas (I- a), (ll-a), (lll-a), (IV-a) or (V-a):
- the invention provides a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, for use in the treatment of a bacterial infection.
- a pharmaceutical composition comprising a compound of any of formulas (l-a), (ll-a), (lll-a), (IV- a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, and one or more pharmaceutically acceptable carriers, for use in the treatment of a bacterial infection.
- Another related aspect provides a method for treating a bacterial infection in a subject in need of such treatment, comprising administering to said subject a therapeutically or prophylactically effective amount of a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof.
- the invention provides a compound of any of formulas (l-a), (ll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, for use as a medicament.
- the invention also provides a pharmaceutical composition comprising a compound of any of formulas (l-a), (ll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, and one or more pharmaceutically acceptable carriers.
- the invention also provides a compound of any of formulas (l-a) or (V-a) as shown above, an ⁇ /-oxide form, addition salt, prodrug or solvate thereof.
- Also provided is a method for inhibition of DD-ligase comprising contacting a DD-ligase, or a composition or a bacterium comprising such, with a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or an ⁇ /-oxide form, addition salt, prodrug or solvate thereof, in an amount sufficient to obtain said inhibition.
- said DD-ligase inhibition may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
- said inhibition of DD-ligase may take place in vitro, more particularly encompassing inhibition of isolated DD-ligase, inhibition of isolated DD- ligase when being a part of a composition, as well as inhibition of DD-ligase in bacteria when said bacteria are outside of a human or animal body.
- isolated when referring to a protein, means that said protein has been identified and separated and/or recovered from a component of its natural environment.
- an isolated protein can be substantially separated from cellular material or other proteins of a cell source from which it is derived.
- an isolated protein may be isolated from its natural source or produced recombinantly.
- Further aspect concerns a method for inhibiting the growth, proliferation and/or survival of bacteria comprising contacting said bacteria with a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or an ⁇ /-oxide form, addition salt, prodrug or solvate thereof, in an amount sufficient to obtain said inhibition.
- said inhibition of bacterial growth, proliferation and/or survival may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
- said inhibition of bacterial growth, proliferation and/or survival may take place ex vivo, which refers to treatments of bacteria outside of a human or animal body.
- ex vivo inhibition may pertain to a method for preserving, disinfecting or sterilising a composition such as for example a liquid solution, device or apparatus contaminated or suspected to be contaminated with bacteria, comprising contacting said composition, device or apparatus with a herein disclosed compound.
- Exemplary devices or apparatuses to be so disinfected or sterilised may include, without limitation, medical or surgical instruments or appliances, such as for example catheters, prosthetic implants, stents, etc.
- surfaces of such devices or apparatuses may be disinfected or sterilised by applying a present compound thereto, e.g., in a solution, in a spray aerosol, etc.
- Exemplary compositions to be so preserved, disinfected or sterilised may include, without limitation, cell culture media for animal cells including inter alia insect or mammalian cells, etc.
- the growth, proliferation and/or survival of bacteria may be inhibited in an in vitro bacterial cell culture, such as for example to assess the sensitivity of a particular bacterial species, subspecies or strain to present compounds, e.g., in clinical or research settings.
- R 5 is selected from hydrogen, d_ 6 alkyl, -OR 6 , -SR 6 , -NR 6 R 7 , and d_ 6 alkyl substituted with one or more substituents selected from halo, hydroxy and oxo, R 6 and R 7 are each independently selected from hydrogen, C h alky!, and
- R 2 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(d_ 6 alkyl)amino, d_ 6 alkylcarbonylamino, d_ 6 alkyl, polyhalod_ 6 alkyl, d_ 6 alkyloxy, carboxyl, d_ 6 alkylcarbonyloxy, d_ 6 alkyloxycarbonyl, each of said groups optionally substituted with one or more substituents selected from halo, hydroxy and d_ 6 alkyloxy;
- R 3 is selected from -NHR 10 and nitro,
- R 10 is selected from hydrogen, d_ 6 alkyl, d_ 6 alkylcarbonyl and d_ 6 alkyloxycarbonyl, each of said groups optionally substituted with one or more substituents selected from halo, hydroxy, amino, nitro and d-6alkyloxy;
- R 4 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(d- 6 alkyl)amino, d_ 6 alkylcarbonylamino, d_ 6 alkyl, polyhalod-ealkyl and d_ 6 alkyloxy, each of said groups being optionally substituted with one or more substituents selected from halo, hydroxy, amino, nitro and d_ 6 alkyloxy.
- the invention provides a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, for use in the treatment of a bacterial infection.
- composition comprising a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, and one or more pharmaceutically acceptable carriers, for use in the treatment of a bacterial infection.
- Another related aspect provides a method for treating a bacterial infection in a subject in need of such treatment, comprising administering to said subject a therapeutically or prophylactically effective amount of a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof.
- DD-ligase inhibition comprising contacting a DD-ligase, or a composition or a bacterium comprising such, with a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof, in an amount sufficient to obtain said inhibition.
- said DD-ligase inhibition may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
- said inhibition of DD-ligase may take place in vitro, more particularly encompassing inhibition of isolated DD-ligase, inhibition of isolated DD-ligase when being a part of a composition, as well as inhibition of
- DD-ligase in bacteria when said bacteria are outside of a human or animal body.
- Further aspect concerns a method for inhibiting the growth, proliferation and/or survival of bacteria comprising contacting said bacteria with a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof, in an amount sufficient to obtain said inhibition.
- said inhibition of bacterial growth, proliferation and/or survival may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
- said inhibition of bacterial growth, proliferation and/or survival may take place ex vivo, which refers to treatments of bacteria outside of a human or animal body. Exemplary ex vivo applications are described elsewhere in this application.
- a sixth group of preferred compounds of formula (Vl) in the foregoing aspects consists of compounds of any of formulas (l-b), (ll-b), (lll-b), (IV-b) or (V-b):
- V-b or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, wherein: p is 0, 1 or 2, preferably p is 0 or 1 , more preferably p is 0; r is 0, 1 or 2, preferably r is 0 or 1 , very preferably r is 0 or very preferably r is 1 ; R 6 is selected from hydrogen, d-ealkyl, and d-ealkyl substituted with one or more substituents selected from halo, hydroxy, Ci_ 6 alkyloxy, carboxyl, Ci_ 6 alkyloxycarbonyl and d-ealkylcarbonyloxy, preferably R 6 is hydrogen or C h alky!, very preferably R 6 is hydrogen or very preferably R 6 is C h alky!; R 2 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(C 1 _ 6 alkyl)amino,
- a seventh group of preferred compounds of formula (Vl) in the foregoing aspects consists of compounds of any of formulas (l-c), (ll-c), (lll-c), (IV-c) or (V-c): or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof, wherein:
- R 2 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(Ci-6alkyl)amino, d-ealkylcarbonylamino, d-ealkyl, polyhalod-ealkyl, d-ealkyloxy, carboxyl, d-ealkylcarbonyloxy, d-ealkyloxycarbonyl, each of said groups optionally substituted with one or more substituents selected from halo, hydroxy and Ci_ 6 alkyloxy, preferably R 2 is selected from hydrogen, halo, hydroxy, d-ealkyl, polyhalod_ 6 alkyl and d_ 6 alkyloxy, more preferably R 2 is hydrogen or halo;
- R 4 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(d_ 6 alkyl)amino, d- 6 alkylcarbonylamino, d_ 6 alkyl, polyhalod-ealkyl and d_ 6 alkyloxy, each of said groups being optionally substituted with one or more substituents selected from halo, hydroxy, amino, nitro and d- 6 alkyloxy, preferably R 4 is selected from hydrogen, halo, hydroxy, d- 6 alkyl, polyhalod-ealkyl and d-ealkyloxy; more preferably R 4 is hydrogen; R 11 is halo, preferably R 11 is fluoro, chloro, bromo or iodo, more preferably R 11 is bromo; R 12 is d_ 6 alkyl, preferably R 12 is methyl or ethyl, more preferably R 12 is ethyl.
- An eighth group of preferred compounds of formula (Vl) in the foregoing aspects consists of compounds of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a), or an ⁇ /-oxide form, addition salt, prodrug or solvate thereof, as defined above wherein.
- the invention provides a compound of any of formulas (l-b), (ll-b), (IV-b) or (V-b) as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, for use as a medicament.
- the invention also provides a pharmaceutical composition comprising a compound of any of formulas (l-b), (ll-b), (IV-b) or (V-b) as defined above, or a pharmaceutically acceptable N- oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, and one or more pharmaceutically acceptable carriers.
- the invention provides a compound of any of formulas (l-c), (ll-c), (IV-c) or (V-c) as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, for use as a medicament.
- the invention also provides a pharmaceutical composition comprising a compound of any of formulas (l-c), (ll-c), (IV-c) or (V-c) as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, and one or more pharmaceutically acceptable carriers.
- the invention also provides a compound of any of formulas (l-b) or (V-b) as defined above, an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof.
- an aspect relates to further compounds capable of establishing bonds with amino acids of DD-ligase enzyme cavity comprising bonds with Glu68, Tyr210 and Arg255 or amino acids equivalent thereto, as well as to uses of such compounds as DD-ligase inhibitors and antibacterial agents, analogously as described herein.
- the invention also relates to processes for the preparation of the herein disclosed compounds, and particularly compounds of formula (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (ll-c), (lll-c), (IV-c) or (V-c) as defined herein, ⁇ /-oxide forms, addition salts, prodrugs, solvates or stereochemically isomeric forms thereof, as taught herein.
- Figure 1 illustrates inhibition of isolated D-alanine-D-alanine ligase (DdI) by the present compounds compared to D-cycloserine.
- X-axis tested compound.
- Y-axis residual activity (% of control).
- Figure 2 illustrates DdI concentration-inhibition relationships for the present compounds ll-a (B), l-a (C) and IV-a (D) compared to D-cycloserine (A).
- X-axis log[inhibitor] (mM).
- Y-axis activity of the ligase (%).
- the Summary section discloses aspects and embodiments of the invention that involve compounds, more particularly compounds of any of formulas (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (ll-c), (lll-c), (IV-c) or (V-c) as defined above, or pharmaceutically acceptable ⁇ /-oxide forms, addition salts, prodrugs, solvates or stereochemical ⁇ isomeric forms thereof, as well as preferred subgroups of such substances.
- Ci_ 6 alkyl defines straight- and branched-chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 2-methylpropyl, 2-methyl-butyl, 2-methylpentyl and the like.
- Polyhalod- ⁇ alkyl defines a Ci-6alkyl as defined herein, wherein two or more hydrogens of said C h alky!
- substituted denotes that one or more hydrogens on one or more atoms (typically C, N, O or S atoms, usually C atoms) of a group indicated by the modifier "substituted” is replaced with a selection from the recited group, provided that the normal valency of the atoms of the indicated group is not exceeded, and that the substitution results in a chemically stable compound, i.e., a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an useful agent.
- one or more covers the possibility of one, more or all available atoms of an indicated group to be substituted where appropriate; preferably of one, two or three, more preferably of one or two, and even more preferably of one available atoms of an indicated group to be substituted.
- addition salt comprises salts which the present compounds are able to form with organic or inorganic bases such as amines, alkali metal bases and earth alkaline metal bases, or quaternary ammonium bases, or with organic or inorganic acids, such as mineral acids, sulfonic acids, carboxylic acids or phosphorus containing acids.
- organic or inorganic bases such as amines, alkali metal bases and earth alkaline metal bases, or quaternary ammonium bases
- organic or inorganic acids such as mineral acids, sulfonic acids, carboxylic acids or phosphorus containing acids.
- addition salt further comprises pharmaceutically acceptable salts, metal complexes and the salts thereof, that the present compounds are able to form.
- pharmaceutically acceptable salts means pharmaceutically acceptable acid or base addition salts.
- the pharmaceutically acceptable acid or base addition salts are meant to comprise therapeutically active non-toxic acid and non-toxic base addition salt forms which the present compounds are able to form.
- the present compounds which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid.
- Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g., hydrochloric or hydrobromic acid, sulphuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e., butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
- inorganic acids such as hydrohalic acids, e.g., hydrochloric or hydrobromic acid, sulphuric, nitric, phosphoric and the like acids
- organic acids such as, for example,
- the present compounds which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base.
- suitable organic or inorganic base e.g., the ammonium salts, the alkali and earth alkaline metal salts, e.g., the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g., the benzathine, N- methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
- acid or base addition salt also comprise the hydrates and the solvent addition forms thereof which the present compounds are able to form. Examples of such forms are, e.g., hydrates, alcoholates and the like.
- metal complexes means a complex formed between a present compound and one or more organic or inorganic metal salt or salts.
- organic or inorganic salts comprise the halogenides, nitrates, sulfates, phosphates, acetates, trifluoroacetates, trichloroacetates, propionates, tartrates, sulfonates, e.g., methylsulfonates, 4-methylphenylsulfonates, salicylates, benzoates and the like of the metals of the second main group of the periodical system, e.g., the magnesium or calcium salts, of the third or fourth main group, e.g., aluminium, tin, lead, as well as the first to the eighth transition groups of the periodical system such as, for example, chromium, manganese, iron, cobalt, nickel, copper, zinc and the like.
- stereochemically isomeric forms of present compounds as used herein, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the present compounds may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the present compounds both in pure form or in admixture with each other are intended to be embraced.
- stereoisomerically pure concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e., minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e., 100% of one isomer and none of the other), more preferably, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more preferably having a stereoisomeric excess of 94% up to 100% and most preferably having a stereoisomeric excess of 97% up to 100%.
- enantiomerically pure and “diastereomerically pure” should be understood in a similar way, but then having regard to the enantiomeric excess and the diastereomeric excess of the mixture in question, respectively.
- the ⁇ /-oxide forms of the present compounds are meant to comprise those compounds wherein one or several nitrogen atoms are oxidized to the so-called ⁇ /-oxide.
- the present compounds may form solvates, for example, with water (i.e., hydrates) or common organic solvents.
- solvate means a physical association of the present compounds with one or more solvent molecules. This physical association involves varying degrees of ionic and other bonding, including hydrogen bonding.
- solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- solvate is intended to encompass both solution-phase and isolatable solvates.
- suitable solvates include ethanolates, methanolates, and the like.
- the present compounds may have one or more crystalline or amorphous polymorph forms, as such intended to be embraced.
- isotopes of atoms present in the present compounds include tritium and deuterium and isotopes of carbon include
- Prodrugs of the present compounds are substances that readily undergo chemical changes under physiological conditions (in vivo) to provide the present compounds. Additionally, prodrugs can be converted to the present compounds by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the present compounds when placed in a trans-dermal patch reservoir with a suitable enzyme or chemical reagent.
- prodrug means pharmacologically acceptable derivatives such as, e.g., esters, amides and phosphates, such that the resulting in vivo biotransformation product of the derivative are the active compounds as defined above.
- Prodrugs of the present compounds are prepared by modifying functional groups present in a compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo or ex vivo, to the parent compound.
- Prodrugs may include substances wherein a hydroxy group or an amino group is bonded to any group that, when the prodrug is administered to a patient, cleaves to form a free hydroxyl or free amino, respectively.
- prodrugs are described for instance in WO 99/33795, WO 99/33815, WO 99/33793 and WO 99/33792 all incorporated herein by reference. Prodrugs are usually characterised by excellent aqueous solubility, increased bioavailability and are readily metabolised into the active inhibitors in vivo.
- the term "present compounds” is meant to include also the N- oxide forms, the acid or base addition salts particularly the pharmaceutically acceptable acid or base addition salts, the prodrugs, the solvates and all stereoisomeric forms of the compounds as defined in the Summary section, more particularly of compounds of any of formulas (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (ll-c), (III- c), (IV-c) or (V-c) as defined above, or compounds of any preferred subgroups thereof.
- the compounds of formula (Vl) wherein R 3 is -NH 2 herein termed compounds of formula (Vl- i) can be prepared from compounds of formula (Vl) wherein R 3 is -NO 2 , herein termed compounds of formula (Vl-ii), by a nitro to amine reduction reaction, for example in the presence of a metal catalyst such as Raney Nickel and an appropriate reductant such as hydrogen, or using sodium dithionite or another suitable reducing agent, in a suitable solvent such as methanol or ethanol:
- the compounds of formula (Vl) can also be prepared from intermediates of formula (IX) by cyclocondensation at elevated temperatures in the presence of a suitable acid catalyst such as HCI or p-toluenesulfonic acid in an appropriate solvent such ethanol: (IX)
- Intermediates of formula (IX) can be prepared from intermediates of formula (Xl) by demethylation such as using boron tribromide (BBr 3 ) in a suitable solvent such as dichloromethane:
- any of the processes for preparation of the present compounds and intermediates it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protecting Groups, P. Kocienski, Thieme Medical Publishers,
- the protecting groups may be removed at a convenient subsequent stage using methods known in the art.
- suitable solvents which may be readily selected by one of skill in the art of organic synthesis, said suitable solvents generally being any solvent which is substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which may range from the solvent's freezing temperature to the solvent's boiling temperature.
- a given reaction may be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step may be selected.
- intermediates and/or final compounds may, if necessary for the following steps and/or for monitoring the reaction, be worked-up and/or purified by methods known in the field of organic synthetic chemistry, such as filtering, solvent extraction, solvent evaporation by heat or under vacuum, re-crystallisation, trituration, chromatography or a method using an ion exchange resin.
- the present compounds represent useful antibacterial agents, i.e., substances which are destructive to or prevent the growth of bacteria, particularly suitable for the treatment of bacterial infections in subjects in need thereof.
- the present compounds are also suitable for inhibiting the growth, proliferation and/or survival of bacteria in vivo (i.e., within a subject's body), as well as in ex vivo (i.e., outside of a subject's body) situations.
- subject refers to animals, preferably warm-blooded animals, more preferably vertebrates, and even more preferably mammals specifically including humans and non-human mammals, that have been the object of treatment, observation or experiment.
- mamal includes any animal classified as such, including, but not limited to, humans, domestic and farm animals, zoo animals, sport animals, pet animals, companion animals and experimental animals, such as, for example, mice, rats, hamsters, rabbits, dogs, cats, guinea pigs, cattle, cows, sheep, horses, pigs and primates, e.g., monkeys and apes.
- Preferred patients are human subjects, including both genders and all age categories thereof.
- a phrase such as "a subject in need of treatment” includes subjects that would benefit from treatment of a given condition, particularly of a bacterial infection. Such subjects may include, without limitation, those that have been diagnosed with said condition, those prone to contract or develop said condition and/or those in whom said condition is to be prevented.
- treat encompass both the therapeutic treatment of an already developed disorder, such as the therapy of an already developed bacterial infection, as well as prophylactic or preventative measures, wherein the aim is to prevent or lessen the chances of incidence of an undesired affliction, such as to prevent the chances of contraction and progression of a bacterial infection.
- beneficial or desired clinical results may include, without limitation, alleviation of one or more symptoms or one or more biological markers (e.g., fever, bacterial load, etc.), diminishment of extent of disease, stabilised (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and the like.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- prophylactically effective amount refers to an amount of an active compound or pharmaceutical agent that inhibits or delays in a subject the onset of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician.
- therapeutically effective amount refers to an amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a subject that is being sought by a researcher, veterinarian, medical doctor or other clinician, which may include inter alia alleviation of the symptoms of the disease or disorder being treated. Methods are known in the art for determining therapeutically and prophylactically effective doses for the present compounds.
- bacterial infection refers to the entry and proliferation of a bacterium that is pathogenic to a subject in a bodily tissue of said subject, producing subsequent tissue injury and disease.
- the term also encompasses a "bacterial superinfection" which refers to a secondary infection that occurs after a previous infection; this secondary infection is generally more destructive than the first and is often attributed to bacteria which have become resistant to the antibiotics used to treat the first infection.
- the terms also encompass nosocomial, i.e., hospital-acquired bacterial infections and/or superinfections. The present compounds can reduce bacterial infections and/or superinfections and prevent further infection from developing.
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria comprise DD-ligase activity.
- DD-ligase refers to a class of enzymes which catalyse the formation of a dimer of D-amino acids from the corresponding monomers at the expense of ATP.
- the term encompasses D-alanine-D-alanine ligases (EC 6.3.2.4) which catalyse the reaction ATP + 2 D-alanine — > ADP + phosphate + D- alanyl-D-alanine.
- DD-ligases which can employ other D-amino acid substrates, such as for example D-alanine-D-serine ligases and D-alanine-D-lactate ligases.
- D-amino acid substrates such as for example D-alanine-D-serine ligases and D-alanine-D-lactate ligases.
- the presence of DD-ligase activity in bacteria or lysates thereof may be tested in known enzymatic assays, such as ones analogous to that shown in the examples.
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria comprise peptidoglycan.
- peptidoglycan refers to a glycopeptide polymer that is a component of bacterial cell walls, and is generally characterised as comprising ⁇ -(1 ,4) linked N-acetylglucosamine (NAG) and N- acetylmuramic acid chains cross-linked by oligopeptide units comprising D-amino acids.
- NAG N-acetylglucosamine
- the present compounds can advantageously interfere with the synthesis of peptidoglycan and hence combat bacteria comprising such.
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are Gram-positive bacteria, Gram-negative bacteria, aerobic bacteria, anaerobic bacteria or mycobacteria.
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are Gram-positive bacteria. Due to high peptidoglycan content in Gram-positive bacteria, the present compounds which inhibit peptidoglycan synthesis may be particularly effective in said bacteria.
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are chosen, by preference but without limitation, from the genera
- Acinetobacter Bacillus, Bacteroides, Campylobacter, Clostridium, Corynebacterium,
- Klebsiella Legionella, Listeria, Moraxella, Mycobacterium, Mycoplasma, Neisseria, Porphyromonas, Prevotella, Proteus, Pseudomonas, Salmonella, Serratia, Staphylococcus,
- Streptococcus and Vibrio, particularly wherein said bacteria represent pathogenic species of said genera.
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are chosen, by preference but without limitation, from Staphylococcus aureus; Staphylococcus epidermidis and other coagulase-negative staphylococci; Streptococcus pyogenes; Streptococcus pneumoniae; Streptococcus agalactiae; Enterococcus species; Corynebacterium diphtheriae; Listeria monocytogenes; Bacillus anthracis; Neisseria meningitidis; Neisseria gonorrhoeae; Moraxella catarrhalis; Vibrio cholerae; Campylobacter jejuni; Enterobacteriaceae (including Escherichia, Salmonella, Klebsiella, Enterobacter); Pseudomonas aeruginosa; Acinetobacter species; Ha
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are resistant to other inhibitors of cell wall synthesis, such as particularly to ⁇ -lactam antibiotics (e.g., penicillins, cephalosporins) or to vancomycin.
- ⁇ -lactam antibiotics e.g., penicillins, cephalosporins
- vancomycin vancomycin
- the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are vancomycin-sensitive or vancomycin-resistant.
- vancomycin-resistant bacteria that may be inhibited include, without limitation, vancomycin- resistant Staphylococcus aureus, Staphylococcus epidermis, vancomycin-resistant Enterococci such as for example vancomycin-resistant Enterococcus faecalis, Enterococcus faecium, Enterococcus casseliflavus and Enterococcus gallinarum, and vancomycin-resistant Clostridium innocuum.
- the present compounds may also represent useful inhibitors of DD-ligases as defined above.
- the term “inhibition” encompasses any extent of inhibition of DD-ligase activity, in particular of its enzymatic activity, such as, e.g., inhibition by at least about 10%, by at least about 20%, by at least about 30%, by at least about 40%, by at least about 50%, by at least about 60%, by at least about 70%, by at least about 80%, by at least about 90%, or even by about 100%, compared to DD-ligase activity in the absence of the inhibitor.
- the extent of DD-ligase inhibition may be measured by assays known in the art, such as described in the examples.
- the present compounds may be advantageously formulated as pharmaceutical formulations for treating bacterial infections.
- compositions comprise one or more present compounds or pharmaceutically acceptable N-oxide forms, acid or base addition salts, prodrugs, solvates or stereoisomeric forms thereof (i.e., one or more "active substances"), and one or more pharmaceutically acceptable carrier/excipient.
- carrier or “excipient” includes any and all solvents, diluents, buffers (such as, e.g., neutral buffered saline or phosphate buffered saline), solubilisers, colloids, dispersion media, vehicles, fillers, chelating agents (such as, e.g., EDTA or glutathione), amino acids (such as, e.g., glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavourings, aromatisers, thickeners, agents for achieving a depot effect, coatings, antifungal agents, preservatives, antioxidants, tonicity controlling agents, absorption delaying agents, and the like.
- buffers such as, e.g., neutral buffered saline or phosphate buffered saline
- solubilisers such as, e.g., EDTA or glutathi
- Illustrative, non-limiting carriers for use in formulating the pharmaceutical compositions include, for example, oil-in-water or water-in-oil emulsions, aqueous compositions with or without inclusion of organic co-solvents suitable for intravenous (IV) use, liposomes or surfactant-containing vesicles, microspheres, microbeads and microsomes, powders, tablets, capsules, suppositories, aqueous suspensions, aerosols, and other carriers apparent to one of ordinary skill in the art.
- compositions of the invention may be formulated for essentially any route of administration, such as without limitation, oral administration (such as, e.g., oral ingestion or inhalation), intranasal administration (such as, e.g., intranasal inhalation or intranasal mucosal application), parenteral administration (such as, e.g., subcutaneous, intravenous, intramuscular, intraperitoneal or intrasternal injection or infusion), transdermal or transmucosal (such as, e.g., oral, sublingual, intranasal) administration, topical administration, rectal, vaginal or intra-tracheal instillation, and the like.
- oral administration such as, e.g., oral ingestion or inhalation
- intranasal administration such as, e.g., intranasal inhalation or intranasal mucosal application
- parenteral administration such as, e.g., subcutaneous, intravenous, intramuscular
- compositions of the invention can be, for example, systemic, local, tissue-specific, etc., depending of the specific needs of a given application of the invention.
- pharmaceutical compositions may be formulated in the form of pills, tablets, lacquered tablets, coated (e.g., sugar-coated) tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions.
- preparation of oral dosage forms may be is suitably accomplished by uniformly and intimately blending together a suitable amount of the active compound in the form of a powder, optionally also including finely divided one or more solid carrier, and formulating the blend in a pill, tablet or a capsule.
- solid carriers include calcium phosphate, magnesium stearate, talc, sugars (such as, e.g., glucose, mannose, lactose or sucrose), sugar alcohols (such as, e.g., mannitol), dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Compressed tablets containing the pharmaceutical composition can be prepared by uniformly and intimately mixing the active ingredient with a solid carrier such as described above to provide a mixture having the necessary compression properties, and then compacting the mixture in a suitable machine to the shape and size desired.
- Moulded tablets maybe made by moulding in a suitable machine, a mixture of powdered compound moistened with an inert liquid diluent.
- Suitable carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc.
- compositions may be formulated with illustrative carriers, such as, e.g., as in solution with saline, polyethylene glycol or glycols, DPPC, methylcellulose, or in mixture with powdered dispersing agents, further employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilising or dispersing agents known in the art.
- illustrative carriers such as, e.g., as in solution with saline, polyethylene glycol or glycols, DPPC, methylcellulose, or in mixture with powdered dispersing agents, further employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilising or dispersing agents known in the art.
- Suitable pharmaceutical formulations for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the compounds of the invention or their physiologically tolerable salts in a pharmaceutically acceptable solvent, such as ethanol or water, or a mixture of such solvents.
- a pharmaceutically acceptable solvent such as ethanol or water, or a mixture of such solvents.
- the formulation can also additionally contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers as well as a propellant.
- delivery may be by use of a single-use delivery device, a mist nebuliser, a breath-activated powder inhaler, an aerosol metered-dose inhaler (MDI) or any other of the numerous nebuliser delivery devices available in the art.
- MDI aerosol metered-dose inhaler
- mist tents or direct administration through endotracheal tubes may also be used.
- carriers for administration via mucosal surfaces depend upon the particular route, e.g., oral, sublingual, intranasal, etc.
- illustrative examples include pharmaceutical grades of mannitol, starch, lactose, magnesium stearate, sodium saccharide, cellulose, magnesium carbonate and the like, with mannitol being preferred.
- illustrative examples include polyethylene glycol, phospholipids, glycols and glycolipids, sucrose, and/or methylcellulose, powder suspensions with or without bulking agents such as lactose and preservatives such as benzalkonium chloride, EDTA.
- the phospholipid 1 ,2 dipalmitoyl-sn- glycero-3-phosphocholine (DPPC) is used as an isotonic aqueous carrier at about 0.01-0.2% for intranasal administration of the compound of the subject invention at a concentration of about 0.1 to 3.0 mg/ml.
- compositions may be advantageously formulated as solutions, suspensions or emulsions with suitable solvents, diluents, solubilisers or emulsifiers, etc.
- suitable solvents are, without limitation, water, physiological saline solution or alcohols, e.g. ethanol, propanol, glycerol, in addition also sugar solutions such as glucose, invert sugar, sucrose or mannitol solutions, or alternatively mixtures of the various solvents mentioned.
- the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- suitable non-toxic, parenterally-acceptable diluents or solvents such as mannitol, 1 ,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- suitable dispersing or wetting and suspending agents such as sterile, bland, fixed oils, including synthetic
- a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600 and the balance USP Water for Injection (WFI).
- Other illustrative carriers for intravenous use include 10% USP ethanol and USP WFI; 0.01-0.1 % triethanolamine in USP WFI; or 0.01- 0.2% dipalmitoyl diphosphatidylcholine in USP WFI; and 1-10% squalene or parenteral vegetable oil-in-water emulsion.
- Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose in WFI and 0.01-0.1 % triethanolamine in 5% dextrose or 0.9% sodium chloride in USP WFI, or a 1 to 2 or 1 to 4 mixture of 10% USP ethanol, 40% propylene glycol and the balance an acceptable isotonic solution such as 5% dextrose or 0.9% sodium chloride; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI and 1 to 10% squalene or parenteral vegetable oil-in-water emulsions.
- PBS phosphate buffered saline
- aqueous formulations may comprise one or more surfactants.
- the composition can be in the form of a micellar dispersion comprising at least one suitable surfactant, e.g., a phospholipid surfactant.
- phospholipids include diacyl phosphatidyl glycerols, such as dimyristoyl phosphatidyl glycerol (DPMG), dipalmitoyl phosphatidyl glycerol (DPPG), and distearoyl phosphatidyl glycerol (DSPG), diacyl phosphatidyl cholines, such as dimyristoyl phosphatidylcholine (DPMC), dipalmitoyl phosphatidylcholine (DPPC), and distearoyl phosphatidylcholine (DSPC); diacyl phosphatidic acids, such as dimyristoyl phosphatidic acid (DPMA), dipahnitoyl phosphatidic acid (DPPA), and distearoyl phosphatidic acid (DSPA); and diacyl phosphatidyl ethanolamines such as dimyristoyl phosphatidyl ethanolamine (DPME), dipalmitoyl phosphatid
- a surfactant: active substance molar ratio in an aqueous formulation will be from about 10:1 to about 1 :10, more typically from about 5:1 to about 1 :5, however any effective amount of surfactant may be used in an aqueous formulation to best suit the specific objectives of interest.
- these formulations may be prepared by mixing the compounds according to the invention with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
- Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
- the present active substances may be used alone or in combination with any antimicrobial therapies and antibiotics known in the art ("combination therapy").
- Combination therapies as contemplated herein may comprise the administration of at least one active substance of the present invention and at least one other pharmaceutically or biologically active ingredient.
- Said present active substance(s) and said pharmaceutically or biologically active ingredient(s) may be administered in either the same or different pharmaceutical formulation(s), simultaneously or sequentially in any order.
- antibiotics in combination therapy with which the present active substances may be employed include, without limitation, ⁇ -lactam antibiotics (such as, e.g., penicillins and cephalosporins), sulfonamide antibiotics, aminoglycoside antibiotics, carbapenems, trimethoprim, chloramphenicol, glycopeptide antibiotics such as vancomycin, macrolides, quinoline antibiotics, tetracyclines, etc.
- ⁇ -lactam antibiotics such as, e.g., penicillins and cephalosporins
- sulfonamide antibiotics aminoglycoside antibiotics
- carbapenems trimethoprim
- chloramphenicol chloramphenicol
- glycopeptide antibiotics such as vancomycin, macrolides, quinoline antibiotics, tetracyclines, etc.
- the dosage or amount of the present active substances used, optionally in combination with one or more other active compound to be administered, depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, body weight, general health, diet, mode and time of administration, and individual responsiveness of the human or animal to be treated, on the route of administration, efficacy, metabolic stability and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to the agent(s) of the invention.
- a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg of body weight or more, depending on the factors mentioned above.
- the treatment is sustained until a desired suppression of disease symptoms occurs.
- a preferred dosage of the active substance of the invention may be in the range from about 0.05 mg/kg to about 10 mg/kg of body weight.
- one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
- Such doses may be administered intermittently, e.g., every week or every three weeks.
- This invention also provides a method for treating or protecting plants from bacterial infection by applying an effective amount of the present compounds to the foliage, roots or the soil surrounding the plants or roots.
- said plants may be treated with compounds of any of formulas (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (II- c), (I I l-c), (IV-c) or (V-c) as defined above, or ⁇ /-oxide forms, addition salts, prodrugs, solvates or stereochemical ⁇ isomeric forms thereof, as well as preferred subgroups of such substances.
- the present compounds can be combined with known pesticides or insecticides.
- Suitable formulations will be known to those skilled in the art.
- compounds within the present invention when used to treat or protect plants from antibiotic resistant bacterial infections can be formulated as wettable powders, granules and the like, or can be microencapsulated in a suitable medium and the like.
- examples of other formulations include, but are not limited to soluble powders, wettable granules, dry flowables, aqueous flowables, wettable dispersible granules, emulsifiable concentrates and aqueous suspensions.
- Other suitable formulations will be known to those skilled in the art.
- Escherichia coli LMG 194 (Invitrogen) was the host strain for recombinant plasmids.
- Total DNA from Enterococcus faecalis JH2-2 (Jacob & Hobbs 1974. J Bacteriol 117: 360-372) was prepared as described (Le Bouguenec et al. 1990. J Bacteriol 172: 727-734) and D-AIa-D-AIa gene was amplified by PCR using the pfu polymerase (Promega) and the primers 1 and 2
- the resulting plasmid encodes for Ddl-His6 protein under the control of a L-arabinose inducible promoter (Guzman et al. 1995. J Bacteriol 177: 4121-4130). Constructed plasmid was transformed into compete strain of LMG194 E. coli for expression.
- the cultures were centrifuged 15 minutes at 4000 rpm and cell pellets were resuspended in cold buffer A (Buffer A : Hepes 50 mM pH 8.0, MgCI 2 5mM, imidazole 10 mM, glycerol 10%) by concentring 2Ox. All following steps of purification were performed in 4°C. Bacteria were disrupted twice by passage in a French Press (operated at 1000 psi) and centrifuged at 18000 g during 30 min.
- Buffer A Hepes 50 mM pH 8.0, MgCI 2 5mM, imidazole 10 mM, glycerol 10%
- HisLink resin Promega
- HisLink resin Promega
- Lysate was removed and the resin was placed on a column and washed with buffer A (30 ml of buffer A for 5 ml of HisLink slurry).
- His- tagged proteins were eluted by adding buffer B (10 ml for 5 ml of HisLink slurry) ( Buffer B : Hepes 50 mM pH 8.0, MgCI2 5mM, NaCI 300 mM, imidazole 500 mM, glycerol 10%).
- Elution fraction was dialysed twice (for 2h and overnight) against buffer C (Buffer C : Hepes 50 mM pH 7.2, KCI 15O mM, MgCI2 5 mM, GSH 5 mM and glycerol 20% ; 2 L of buffer C for 150ml of elution buffer).
- buffer C Buffer C : Hepes 50 mM pH 7.2, KCI 15O mM, MgCI2 5 mM, GSH 5 mM and glycerol 20% ; 2 L of buffer C for 150ml of elution buffer.
- proteins fractions were analyzed for purity by SDS- polyacrylamide gel electrophoresis (Novex tris-Glycine Gels 14%, Invitrogen); one unique band was obtained at -42 kDa. Protein concentrations were determined by the method of Bradford using bovine serum albumin as standard (Quick Start Bradford Protein Assay, BioRad). Pure fractions are stored in buffer C at -80 0
- Activity of the His-tagged DdI ligase was determined by measuring the quantity of D- AIa-D- AIa produced from D-AIa using D-[ 14 C]AIa.
- Assay mixtures (10 ⁇ l) contained Tris-HCI 20 mM pH 7.4, MgCI2 10 mM, KCI 10 mM, ATP 5 mM, enzyme ( 0.1 to 3 ⁇ g) and mixture of D-[1- 14 C]AIa 10 mM (Moravek: 51 mCi/mmol, 0.1 mCi/ml) and unlabeled D-AIa to a final concentration of 10 mM at 0.02 ⁇ Ci.
- molecules for testing the effect of inhibitors, molecules (at suitable concentration(s)) were preincubated for 5 min with the enzyme in the above assay mixture before addition of ATP and D-[ 14 C]AIa (in a volume of 20 ⁇ l). Depending of the water-solubility of each inhibitor, up to 10% of DMSO was added in reaction buffer. The mixture was incubated 30 min at 30 0 C. The reaction was stopped by boiling the samples for 5 min (immersion in a water bath set at 100 0 C), and centrifuged 10 min at 13,000 rpm.
- the corresponding fragments were used for determination of their radioactivity by placing them in vials containing 10 ml of scintillation mixture (Ultima Gold from PerkinElmer) and by counting samples in a Packard TriCarb Liquid scintillation analyser (1900TR) with an efficiency of 95%.
- scintillation mixture Ultima Gold from PerkinElmer
- the percentage of conversion of D-AIa into the dimmer was calculated, and enzyme activity expressed as moles of product released per minute and per mg of enzyme.
- D-AIa-D-AIa ligase has been purified from Enterococcus faecalis JH2-2. More than 1 g has been obtained from 12 L of induced bacterial culture with a purification factor of about 2 and a yield of about 65%. The activity of the pure enzyme was about 1.5 nmol/min/ ⁇ g at 30 0 C.
- the invention also relates to a process for preparation of a compound of any of formula (l-a), (ll-a), (lll-a) (IV-a) and (V-a) as taught in above schemes 1 , 2, 3, 4 and 5, respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Cette invention concerne des composés utilisés comme agents antibactériens, des processus permettant de les préparer, et des compositions comprenant lesdits agents, lesdits composés étant de formule (VI) et r, p, R1, R2, R3 et R4 ayant les significations énoncées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07150355 | 2007-12-21 | ||
EP07150355.1 | 2007-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009080788A2 true WO2009080788A2 (fr) | 2009-07-02 |
WO2009080788A3 WO2009080788A3 (fr) | 2010-05-20 |
Family
ID=39744739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/068100 WO2009080788A2 (fr) | 2007-12-21 | 2008-12-19 | Agents antibactériens |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009080788A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104788398A (zh) * | 2015-03-24 | 2015-07-22 | 上海交通大学 | 苯并恶唑类化合物及其制备方法和用途 |
GB2571950A (en) * | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
US10526343B2 (en) | 2018-03-26 | 2020-01-07 | University Of Sharjah | Heterocyclic systems and pharmaceutical applications thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074516A1 (fr) * | 2002-03-06 | 2003-09-12 | Oxford Glycosciences (Uk) Ltd | Derives d'acides carboxyliques phtalimidiques |
EP1571142A1 (fr) * | 2004-03-01 | 2005-09-07 | Rottapharm S.p.A. | Dérivés de type amidine hétérocyclique anti-inflammatoires et analgétiques, inhibiteurs de la production de monoxide d'azote (NO) |
WO2007042816A1 (fr) * | 2005-10-12 | 2007-04-19 | Biolipox Ab | Benzoxazoles convenant pour le traitement d'une inflammation |
WO2007091106A2 (fr) * | 2006-02-10 | 2007-08-16 | Summit Corporation Plc | Traitement de la dystrophie musculaire de duchenne |
-
2008
- 2008-12-19 WO PCT/EP2008/068100 patent/WO2009080788A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074516A1 (fr) * | 2002-03-06 | 2003-09-12 | Oxford Glycosciences (Uk) Ltd | Derives d'acides carboxyliques phtalimidiques |
EP1571142A1 (fr) * | 2004-03-01 | 2005-09-07 | Rottapharm S.p.A. | Dérivés de type amidine hétérocyclique anti-inflammatoires et analgétiques, inhibiteurs de la production de monoxide d'azote (NO) |
WO2007042816A1 (fr) * | 2005-10-12 | 2007-04-19 | Biolipox Ab | Benzoxazoles convenant pour le traitement d'une inflammation |
WO2007091106A2 (fr) * | 2006-02-10 | 2007-08-16 | Summit Corporation Plc | Traitement de la dystrophie musculaire de duchenne |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104788398A (zh) * | 2015-03-24 | 2015-07-22 | 上海交通大学 | 苯并恶唑类化合物及其制备方法和用途 |
GB2571950A (en) * | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
US11208391B2 (en) | 2018-03-13 | 2021-12-28 | Azad Pharma Ag | Polymorphs and new path to synthesize Tafamidis |
US10526343B2 (en) | 2018-03-26 | 2020-01-07 | University Of Sharjah | Heterocyclic systems and pharmaceutical applications thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2009080788A3 (fr) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2257296T3 (es) | Nuevas prolinas como agentes antimicrobianos. | |
TWI374138B (en) | 5-hydroxymethyl-oxazolidin-2-one derivatives | |
EP2203219B1 (fr) | Benzamidines substituées utilisées comme agents antibactériens | |
KR20070063546A (ko) | 비만증 치료를 위한 비페닐-4-일-카르보닐아미노산유도체의 제조법 및 용도 | |
TW201249849A (en) | Selective glycosidase inhibitors and uses thereof | |
JP2007505950A (ja) | β−ラクタマーゼ阻害剤およびその使用方法 | |
AU2004258821A1 (en) | Antibacterial methods and compositions | |
US20150051275A1 (en) | Antibacterial agents: sidechainfluorinated myxopyronin derivatives | |
WO2012037508A2 (fr) | Agents antibactériens : dérivés de myxopyronine de puissance élevée | |
EP3180317A1 (fr) | Inhibiteurs du facteur xia | |
EP2725029A1 (fr) | Nouveaux composés antibactériens et leurs applications biologiques | |
EP3247354B1 (fr) | Inhibiteurs du factor xia | |
US20130296421A1 (en) | Arylpropionyl-alpha-pyrone antibacterial agents | |
WO2011081945A2 (fr) | Activation et activateurs de sirt6 | |
WO2013103969A1 (fr) | Agents antibactériens : dérivés du phloroglucinol | |
CN108137574B (zh) | 羟烷基噻二唑衍生物 | |
WO2009080788A2 (fr) | Agents antibactériens | |
WO2012017434A2 (fr) | Composés destinés au traitement d'infections bactériennes | |
EP1280808A1 (fr) | Antibiotiques de la famille des beta-lactamines ameliores | |
WO2008094507A2 (fr) | Nouveaux composés de fusion | |
US20110086813A1 (en) | Compounds for treating bacterial infections | |
KR910000440B1 (ko) | 이미다조[1,5-a]피리딘 유도체의 제조방법 | |
US9282738B2 (en) | Antimicrobial compositions and methods of use thereof | |
US10450292B2 (en) | Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols | |
CN112118837B (zh) | 抗菌剂:o-烷基氘化派洛宁 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08863521 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08863521 Country of ref document: EP Kind code of ref document: A2 |